Use of Pharmacotherapy to Reduce Cue-responsiveness in Smokers

• Status: Completed
• Trial end date: 2006-05-01
• Target enrollment: 0
• Participant gender: All

Summary

In this study we, the investigators at the Centre for Addiction and Mental Health, intend to explore whether bupropion is able to reduce smokers' responses to cigarette-related environmental cues, and craving. Previous studies have indicated that bupropion may be able to achieve these outcomes. Therefore, we predict that smokers treated with bupropion for several weeks will show reduced reactivity to cigarette cues and craving.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Centre for Addiction and Mental Health
• Collaborator: Canadian Institutes of Health Research (CIHR)
• Treatments: Bupropion; Nicotine

Criteria

Inclusion Criteria:

• Males or females

• At least 19 years of age

• Smoking at least 10 cigarettes per day for at least 2 years

• Never treated with bupropion/Zyban

Exclusion Criteria:

• Co-morbid psychiatric disorder

• History of psychotic disorder or eating disorder

• Current alcohol or substance abuse/dependence (excluding nicotine, caffeine)

• Brain injury

• Seizure disorder

• Pregnancy, lactation, or at risk of becoming pregnant

• Current regular use of psychotropic drugs

• Known allergy or sensitivity to bupropion